← All trials
NCT04353830
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 22, 2020
- Primary completion
- Jun 16, 2021
- Completion date
- Dec 31, 2023
- First posted
- Apr 20, 2020
- Last posted
- Apr 20, 2020
- Enrollment
- 270
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Innovent Biologics (Suzhou) Co. Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.